Lycia Therapeutics, Inc. (NASDAQ:LYCA – Get Free Report) was the recipient of a large growth in short interest in the month of October. As of October 30th, there was short interest totaling 304,185 shares. Currently, 0.6% of the company’s stock are sold short. Based on an average daily trading volume, of 400,880 shares, the short-interest ratio is currently 0.8 days.
Insiders Place Their Bets
In related news, major shareholder Venrock Healthcare Capital Par purchased 1,952,705 shares of the business’s stock in a transaction on Monday, October 26th. The shares were purchased at an average price of $18.04 per share, with a total value of $35,226,798.20. Following the completion of the purchase, the insider owned 6,785,437 shares in the company, valued at $122,409,283.48. This represents a 40.41% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders have purchased a total of 2,078,749 shares of company stock valued at $38,526,342 over the last 90 days.
Lycia Therapeutics Stock Performance
Shares of Lycia Therapeutics stock traded down $2.59 during trading on Monday, reaching $28.61. The stock had a trading volume of 250,871 shares, compared to its average volume of 471,117. Lycia Therapeutics has a 52 week low of $22.19 and a 52 week high of $36.49.
Analysts Set New Price Targets
Read Our Latest Stock Report on LYCA
Lycia Therapeutics Company Profile
Lycia Therapeutics is a biotechnology company developing medicines that use its lysosomal targeting chimera (LYTAC) platform to direct disease-related proteins for breakdown inside cells. The approach is designed to address extracellular and cell-surface proteins that may be difficult to target with conventional drug therapies. The company’s work is research and development-focused; it does not have marketed products. Its programs aim to apply targeted protein degradation to conditions including cancer and inflammatory diseases.
See Also
- Five stocks we like better than Lycia Therapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Lycia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lycia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
